• Rebecca L Robinson and Megan L Jones.
• Eli Lilly and Company, US Medical Division, Outcomes Research, Lilly Corporate Center, Indianapolis, IN 46285, USA. rlrobinson@lilly.com
• Expert Opin Pharmacother. 2006 Jun 1;7(8):1027-39.

AbstractFibromyalgia is characterised by chronic widespread pain of unknown aetiology and affects approximately 2% of the population. It can cause significant patient disability, sizeable economic costs, complex management decisions and controversy for healthcare providers. In lieu of uniformly approved treatments for fibromyalgia, patients may try multiple pharmacological and non-pharmacological therapies with questionable efficacy. The literature lacks pharmacoeconomic studies that balance the cost and benefit of interventions. In the absence of this work, cost outcomes are reviewed in this paper. Due to inconclusive results, further study is needed on fibromyalgia treatment cost-effectiveness. These analyses could provide useful information for policy and evidence-based practice guidelines toward optimal disease management. Medical professionals should be a driving force in understanding the clinical and economic challenges of fibromyalgia.

16 keywords...

hide…